Preclinical oncology studies evaluating a structurally diverse range of IDO inhibitors showed promising results; for instance, in murine models of melanoma, the combination of IDO-1 blockade with checkpoint inhibitors significantly decreased xenograft growth and increased local cytotoxic T-cell proliferation [25]. Here, IDO1 is linked to melanoma.